Abstract：Rabies is an old and traditional disease, and its public security threat is still in existence. Human beings need new, fast and cheaper vaccine technology to prevent and control it. As a new type of nucleic acid vaccine, mRNA vaccine has achieved phased progress in the prevention and control of infectious diseases and cancer treatment. Rabies mRNA vaccine is expected to become a new force in the fight against rabies. This article will briefly review the construction, delivery system and preclinical and clinical research of rabies mRNA vaccines, and clarify the current research status of rabies mRNA vaccines.
石磊泰, 李玉华. 狂犬病mRNA疫苗的应用和研究进展[J]. 中国人兽共患病学报, 2021, 37(12): 1123-1128.
SHI Lei-tai, LI Yu-hua. Application and research progress of rabies mRNA vaccine. Chinese Journal of Zoonoses, 2021, 37(12): 1123-1128.
[1] 俞永新. 狂犬病和狂犬病疫苗[M].北京:中国医药科技出版社,2009:5-6. [2] Taylor LH, Hampson K, Fahrion A, et al.Difficulties in estimating the human burden of canine rabies[J]. Acta Tropica, 2017, 165:133-140. DOI:10.1016/j.actatropica.2015.12.007 [3] WHO expert consultation on rabies, 3rd report.Technical report series1012[R].Switzerland:World Health Organization,2018:78-107. [4] Pasteur L. Méthode pour prévenir la rage après morsure[J]. L’Academie Sci, 1885, 101, 765-772. [5] Hicks DJ, Fooks AR, Johnson N.Developments in rabies vaccines[J]. Clin Experiment Immunol, 2012, 169(3):199-204. DOI:10.1111/j.1365-2249.2012.04592.x [6] Wolff JA,Malone RW,Williams P,et al.Direct gene transfer into mouse muscle in vivo[J]. Science,1990,247(4949):1465-1468. DOI:10.1126/science.1690918 [7] Jirikowski G, Sanna P, Maciejewski-Lenoir D, et al.Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA[J]. Science, 1992, 255(5047):996-998. DOI:10.1126/science.1546298 [8] Karikó K, Muramatsu H, Welsh FA, et al.Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability[J].Mol Ther,2008, 16:1833-1840.DOI:10.1038/mt.2008.200 [9] Kauffman KJ, Webber MJ, Anderson DG.Materials for non-viral intracellular delivery of messenger RNA therapeutics[J]. J Control Release,2016, 240:227-234. DOI:10.1016/j.jconrel.2015.12.032 [10] Guan S, Rosenecker J.Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems[J]. Gene Therapy, 2017, 24(3):133-143. DOI:10.1038/gt.2017.5 [11] Thess A, Grund S, Mui B L, et al.Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals[J]. Molecular Therapy, 2015, 23(9):1456-1464. DOI:10.1038/mt.2015.103 [12] Karikó K, Hiromi M, Ludwig J, et al.Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA[J]. Nucleic Acid Res, 2011(21):e142-e142. DOI:10.1093/nar/gkr695 [13] Ziemniak M,Strenkowska M,Kowalska J, et al.Potential therapeutic applications of RNA cap analogs[J]. Future Med Chem, 2013, 5(10): 1141-1172. DOI:10.4155/fmc.13.96 [14] Stepinski J,Waddell C,Stolarski R, et al.Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl(3'-deoxy) GpppG[J]. RNA, 2001,7(10):1486-1495. [15] Zohra FT, Chowdhury EH, Tada S, et al.Effective delivery with enhanced translational activity synergistically accelerates mRNA-based transfection[J]. Biochemic Biophysic Res Commun, 2007, 358(1):373-378.DOI:10.1016/j.bbrc.2007.04.059 [16] Bernstein P, Peltz S W, Ross J.The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro[J]. Molecul Cell Biol, 1989, 9(2):659-670.DOI:10.1128/MCB.9.2.659 [17] Munroe D, Jacobson A. mRNA poly(A) tail, a 3' enhancer of translational initiation[J]. Molecul Cell Biol, 1990, 10(7):3441-3455.DOI:10.1128/MCB.10.7.3441 [18] Elango N, Elango S, Shivshankar P, et al.Optimized transfection of mRNA transcribed from a d(A/T)100 tail-containing vector[J]. Biochemi Biophysic Res Commun, 2005, 330(3):958-966.DOI:10.1016/j.bbrc.2005.03.067 [19] Holtkamp S,Kreiter S,Selmi A, et al.Modification of antigen-encoding RNA increases stability, translational efficacy, and T cell stimulatory capacity of dendritic cells[J]. Blood, 2006, 108(13): 4009-4017. DOI:10.1182/blood-2006-04-015024 [20] Van der velden AW, Thomas AA. The role of the 5' untranslated region of an mRNA in translation regulation during development[J]. Inter J Biochemist Cell Biol, 1999, 31(1):87-106.DOI:10.1016/S1357-2725(98)00134-4 [21] Jansen RP. mRNA localization: message on the move[J]. Nat Rev Mol Cell Biol, 2001, 2(4):247-256.DOI:10.1038/35067016 [22] Mignone F, Gissi C, Liuni S, et al. Untranslated regions of mRNAs[J]. Genome Biol, 2002, 3(3):reviews0004.1-reviews004.10. DOI:10.1186/gb-2002-3-3-reviews0004 [23] Deo RC,Bonanno JB,Sonenberg N,et al.Recognition of polyadenylate RNA by the poly(A)-binding protein[J]. Cell, 1999, 98(6): 835-845. DOI:10.1016/S0092-8674(00)81517-2 [24] Gallie DR, Tanguay RL, Leathers V.The tobacco etch viral 5' leader and poly(A) tail are functionally synergistic regulators of translation[J]. Gene, 1995, 165(2):233-238.DOI:10.1016/0378-1119(95)00521-7 [25] Vivinus S, Baulande S, Zanten MV, et al.An element within the 5' untranslated region of human Hsp70 mRNA which acts as a general enhancer of mRNA translation.[J]. Eur J Biochem, 2010, 268(7):1908-1917.DOI:10.1046/j.1432-1327.2001.02064.x [26] Yakubov E, Rechavi G, Rozenblatt S, et al.Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors[J]. Biochem Biophy Res Commun, 2010, 394(1):189-193. DOI:10.1016/j.bbrc.2010.02.150 [27] Kudla G,Lipinski L,Caffin F, et al.High guanine and cytosine content increases mRNA levels in mammalian cells[J]. PLoS Biol, 2006, 4(6): 933-942. DOI:10.1371/journal.pbio.0040180 [28] Pardi N, Weissman D.Nucleoside Modified mRNA Vaccines for Infectious Diseases[J]. Methods Mol Biol, 2017, 1499: 109-121. DOI:10.1007/978-1-4939-6481-9_6 [29] Karikó K,Muramatsu H,Welsh FA, et al.Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability[J]. Mol Ther, 2008,16(11): 1833-1840. DOI:10.1038/mt.2008.200 [30] Grzegorz, Kudla, Andrew W, et al. Coding-sequence determinants of gene expression in Escherichia coli[J]. Science,2009, 324(5924): 255-258. DOI:10.1126/science.1170160 [31] Buhr F, Jha S, Thommen M, et al.Synonymous codons direct cotranslational folding toward different protein conformations[J]. Molecular Cell, 2016, 61(3): 341-351. DOI:10.1016/j.molcel.2016.01.008 [32] Mauro VP, Chappell SA.A critical analysis of codon optimization in human therapeutics[J]. Other, 2014, 20(11): 604-613. DOI:10.1016/j.molmed.2014.09.003 [33] Brito LA, Kommareddy S, Maione D, et al.Self-amplifying mRNA vaccines.[J]. Adv Gene, 2015, 89:179-233. [34] Pardi N,Hogan MJ, Porter FW, et al.mRNA vaccines-a new era in vaccinology[J]. Nat Rev Drug Discov, 2018,17(4):261-279. DOI:10.1038/nrd.2017.243 [35] 曹雪涛. 医学免疫学[M].北京:人民卫生出版社,2018:92-94. [36] Kranz LM,Diken M,Haas H, et al.Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.[J]. Nature, 2016, 534(7607):396-401. DOI:10.1038/nature18300 [37] Abderraouf S, Fulvia V, Kordula KN, et al.Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice[J]. Cancer Immunol Immun, 2016, 65(9):1075-1083. DOI:10.1007/s00262-016-1869-7 [38] Sahin U, Derhovanessian E,Miller M,et al.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer[J]. Nature, 2017,547:222-226. DOI:10.1038/nature23003 [39] Hoerr I,Obst R,Rammensee HG, et al.In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies[J]. Eur J Immunol, 2000, 30(1):1-7. DOI:10.1002/1521-4141(200001)30 [40] Kallen K J, Heidenreich R, Schnee M, et al.A novel, disruptive vaccination technology:self-adjuvanted RNActive? vaccines[J]. Hum Vacc Immunother, 2013, 9(10):2263-2276. DOI:10.4161/hv.25181 [41] Fotin-MM, Duchardt KM, Lorenz C, et al.Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity[J]. J Immunother, 2011, 34(1):1-15. DOI:10.1097/CJI.0b013e3181f7dbe8 [42] Kanasty R, Dorkin JR, Vegas A, et al.Delivery materials for siRNA therapeutics[J]. Nat Material, 2013, 12(11):967-977. DOI:10.1038/NMAT3765 [43] Norbert, Pardi, Steven, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes[J]. J Control Rel, 2015,217:345-351.DOI:10.1016/j.jconrel.2015.08.007 [44] Geall AJ,Verma A,Otten GR,et al.Nonviral delivery of self-amplifying RNA vaccines[J]. P Nat Acad Sci, 2012, 109(36):14604-14609. DOI:10.1073/pnas.1209367109 [45] Brito LA,Chan M,Shaw CA A,et al.Cationic nanoemulsion for the delivery of next-generation RNA vaccines[J]. Mol Ther, 2014, 22(12):2118-2129. DOI:10.1038/mt.2014.133 [46] Schnee M, Vogel AB, Voss D, et al.An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs[J]. PLoS Neglect Trop Dis, 2016, 10(6):e0004746. DOI:10.1371/journal.pntd.0004746 [47] WHO expert consultation on rabies. Technical report series 931[R].Switzerland:World Health Organization, 2005:1-88, back cover. [48] Wiktor TJ.Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin[J]. Dev Biol Stand, 1978, 40:255-264. [49] Charles ER,Anthony RF,Bernadette AR.Laboratory techniques in rabies[M]. Switzerland: World Health Organization, 2018, 2:192-200. [50] Alberer M,Gnad-Vogt, Hong U,et al.Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial[J]. Lancet,2017,390(10101):1511-1520. DOI:10.1016/S0140-6736(17)31665-3 [51] Armbruster N, Jasny E, Petsch B.Advances in RNA vaccines for preventive indications: a case study of a vaccine against rabies[J]. Vaccines, 2019, 7(4):132. DOI:10.3390/vaccines7040132 [52] Stokes A,Pion J,Binazon O,et al.Nonclinical safety assessment of repeated administration and biodistribution of a novel rabies self-amplifying mRNA vaccine in rats[J]. Regul Toxicol Pharmacol,2020,113:104648. DOI:10.1016/j.yrtph.2020.104648 [53] 刘隽,彭育才,向晟楠,等.一种mRNA狂犬病疫苗:中国,CN110714015A, CN201911042634.2[P].2020-01-21.
2021, Vol. 37 
